MCID: ACT119
MIFTS: 59

Acute Promyelocytic Leukemia

Categories: Genetic diseases, Rare diseases, Cancer diseases, Blood diseases, Immune diseases

Aliases & Classifications for Acute Promyelocytic Leukemia

MalaCards integrated aliases for Acute Promyelocytic Leukemia:

Name: Acute Promyelocytic Leukemia 57 12 76 53 25 59 29 15 73
Acute Myeloblastic Leukemia Type 3 12 76 53
Leukemia, Acute Promyelocytic 57 25 13
Aml M3 53 25 59
Apl 57 12 25
Acute Myeloid Leukemia with T(15;17)(q22;q12);(pml/raralpha) and Variants 53 59
Aml with T(15;17)(q22;q12);(pml/raralpha) and Variants 53 59
Leukemia, Acute Promyelocytic, Somatic 57 40
Acute Myeloblastic Leukemia 3 53 59
Apml 53 59
Leukemia, Promyelocytic, Acute 44
Leukemia, Acute, Promyelocytic 40
Leukemia Promyelocytic Acute 55
Myeloid Leukemia, Acute, M3 25
Acute Myeloid Leukemia M3 12
M3 Anll 25

Characteristics:

Orphanet epidemiological data:

59
acute promyelocytic leukemia
Prevalence: 1-9/1000000 (United States),1-9/1000000 (Europe),1-9/1000000 (France); Age of onset: Adult; Age of death: elderly;

HPO:

32
acute promyelocytic leukemia:
Inheritance somatic mutation


Classifications:



External Ids:

OMIM 57 612376
Disease Ontology 12 DOID:0060318
ICD10 33 C92.4 C92.40
MeSH 44 D015473
NCIt 50 C3182
SNOMED-CT 68 110004001 28950004
Orphanet 59 ORPHA520
UMLS via Orphanet 74 C0023487
MESH via Orphanet 45 D015473
ICD10 via Orphanet 34 C92.4
MedGen 42 C0023487
SNOMED-CT via HPO 69 124975008
UMLS 73 C0023487

Summaries for Acute Promyelocytic Leukemia

NIH Rare Diseases : 53 Acute promyelocytic leukemia (APL) is an aggressive type of acute myeloid leukemia in which there are too many immature blood-forming cells (promyelocytes) in the blood and bone marrow. This build up of promyelocytes leads to a shortage of normal white and red blood cells and platelets in the body. The signs and symptoms of APL include an increased risk to both bleed and form blood clots. Individuals may also experience excessive tiredness, pain in affected areas, loss of appetite, and weight loss. APL usually occurs in middle-aged adults, but can be diagnosed at any age. It is caused by a mutation that is acquired over a person's lifetime, usually involving a translocation between chromosomes 15 and 17. Treatment may include the use of all-trans retinoic acid (ATRA) and arsenic trioxide or anthracycline-based chemotherapy.

MalaCards based summary : Acute Promyelocytic Leukemia, also known as acute myeloblastic leukemia type 3, is related to leukemia and leukemia, acute myeloid. An important gene associated with Acute Promyelocytic Leukemia is NUMA1 (Nuclear Mitotic Apparatus Protein 1), and among its related pathways/superpathways are MicroRNAs in cancer and miRNAs involved in DNA damage response. The drugs Trisenox and Arsenic trioxide have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and bone marrow, and related phenotypes are acute promyelocytic leukemia and abnormal granulocytopoietic cell morphology

Disease Ontology : 12 An acute myeloid leukemia characterized by accumulation of promyelocytes in the bone marrow and by a translocation between chromosomes 15 and 17.

Genetics Home Reference : 25 Acute promyelocytic leukemia is a form of acute myeloid leukemia, a cancer of the blood-forming tissue (bone marrow). In normal bone marrow, hematopoietic stem cells produce red blood cells (erythrocytes) that carry oxygen, white blood cells (leukocytes) that protect the body from infection, and platelets (thrombocytes) that are involved in blood clotting. In acute promyelocytic leukemia, immature white blood cells called promyelocytes accumulate in the bone marrow. The overgrowth of promyelocytes leads to a shortage of normal white and red blood cells and platelets in the body, which causes many of the signs and symptoms of the condition.

OMIM : 57 Acute promyelocytic leukemia (APL) is associated with 2 cardinal features: a granulocytic differentiation block and reciprocal and balanced translocations that always involve rearrangement of the RARA gene (180240). The most frequent translocation is t(15,17)(q21;q22), which fuses the RARA gene with the PML gene (102578) and represents more than 98% of APL (Vitoux et al., 2007). (612376)

Wikipedia : 76 Acute myeloid leukemia (AML) is a cancer of the myeloid line of blood cells, characterized by the rapid... more...

Related Diseases for Acute Promyelocytic Leukemia

Diseases related to Acute Promyelocytic Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 134)
# Related Disease Score Top Affiliating Genes
1 leukemia 33.4 NEAT1 NPM1 PML RARA ZBTB16
2 leukemia, acute myeloid 30.7 MIR126 MIR210 MIR223 MIR23A MIRLET7C NPM1
3 aleukemic leukemia cutis 30.5 NPM1 RARA
4 thyroid cancer, nonmedullary, 1 30.4 MIR15A NEAT1 PRKAR1A
5 leukemia, acute lymphoblastic 30.0 MIR210 MIR223 MIR23A MIRLET7C
6 antiphospholipid syndrome 11.3
7 atrichia with papular lesions 11.2
8 lipodystrophy, partial, acquired 11.1
9 myeloid leukemia 10.5
10 dermatomyositis 10.4 MIR210 MIR223
11 pituitary adenoma 10.3 MIR15A MIR16-1 MIR223
12 disseminated intravascular coagulation 10.3
13 intracranial hypertension, idiopathic 10.3
14 thrombosis 10.3
15 oral squamous cell carcinoma 10.2 MIR126 MIR223 MIR23A NEAT1
16 nonalcoholic fatty liver disease 10.2 MIR126 MIR16-1 MIRLET7C MIRLET7D
17 lymphoma 10.1
18 bone marrow necrosis 10.1
19 myelodysplastic syndrome 10.1
20 acute leukemia 10.1
21 hematopoietic stem cell transplantation 10.1
22 multiple sclerosis 10.1
23 hepatitis 10.1
24 sarcoma 10.1
25 myeloid sarcoma 10.1
26 endotheliitis 10.1
27 leukemia, chronic lymphocytic 10.0 MIR15A MIR16-1 MIR223 NEAT1
28 aging 10.0
29 budd-chiari syndrome 10.0
30 leukemia, chronic myeloid 10.0
31 aplastic anemia 10.0
32 pulmonary fibrosis and/or bone marrow failure, telomere-related, 2 10.0
33 pancytopenia 10.0
34 myeloproliferative neoplasm 10.0
35 pancreatitis 10.0
36 breast cancer 9.9
37 wilms tumor 1 9.9
38 wilms tumor 5 9.9
39 myocardial infarction 9.9
40 hemolytic anemia, cd59-mediated, with or without immune-mediated polyneuropathy 9.9
41 aspergillosis 9.9
42 wilms tumor 6 9.9
43 hemophagocytic lymphohistiocytosis 9.9
44 leukostasis 9.9
45 dermatitis 9.9
46 acute pancreatitis 9.9
47 cerebritis 9.9
48 paralytic ileus 9.9
49 neuropathy 9.9
50 meningitis 9.9

Graphical network of the top 20 diseases related to Acute Promyelocytic Leukemia:



Diseases related to Acute Promyelocytic Leukemia

Symptoms & Phenotypes for Acute Promyelocytic Leukemia

Clinical features from OMIM:

612376

Human phenotypes related to Acute Promyelocytic Leukemia:

32
# Description HPO Frequency HPO Source Accession
1 acute promyelocytic leukemia 32 HP:0004836
2 abnormal granulocytopoietic cell morphology 32 HP:0012135

Drugs & Therapeutics for Acute Promyelocytic Leukemia

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Trisenox 18 49 ARSENIC TRIOXIDE Cell Therapeutics September 2000

Drugs for Acute Promyelocytic Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 199)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Arsenic trioxide Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 1327-53-3 518740
2
Daunorubicin Approved Phase 4,Phase 3,Phase 2,Not Applicable 20830-81-3 30323
3
Idarubicin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58957-92-9 42890
4
Cytarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 147-94-4 6253
5
Mitoxantrone Approved, Investigational Phase 4,Phase 3 65271-80-9 4212
6
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
7
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-18-0, 6055-19-2 2907
8
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 135968-09-1
9
Thiotepa Approved, Investigational Phase 4,Phase 1 52-24-4 5453
10
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3 50-02-2 5743
11
Tretinoin Approved, Investigational, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 302-79-4 5538 444795
12 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
13 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1
14 Dermatologic Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
15 Keratolytic Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
16 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
17 Analgesics Phase 4,Phase 3
18 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
19 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
20 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
21 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
22 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
23 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2
24 6-Mercaptopurine Phase 4,Phase 3,Phase 2
25 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
26 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
27 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
28 Antilymphocyte Serum Phase 4,Phase 2
29 Antiemetics Phase 4,Phase 3,Phase 2
30 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2
31 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2
32 Autonomic Agents Phase 4,Phase 3,Phase 2
33 Gastrointestinal Agents Phase 4,Phase 3,Phase 2
34 glucocorticoids Phase 4,Phase 3,Phase 2
35 Hormone Antagonists Phase 4,Phase 3,Phase 2
36 Hormones Phase 4,Phase 3,Phase 2
37 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2
38 BB 1101 Phase 4,Phase 3
39 Dexamethasone acetate Phase 4,Phase 3 1177-87-3
40
Busulfan Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 55-98-1 2478
41
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
42
Thioguanine Approved Phase 3 154-42-7 2723601
43
Azacitidine Approved, Investigational Phase 3,Phase 2,Phase 1 320-67-2 9444
44
Decitabine Approved, Investigational Phase 3,Phase 2,Phase 1 2353-33-5 451668
45
Amsacrine Approved, Investigational Phase 3 51264-14-3 2179
46
Fludarabine Approved Phase 3,Phase 2,Phase 1 21679-14-1, 75607-67-9 30751
47
Methylprednisolone Approved, Vet_approved Phase 3,Phase 2 83-43-2 6741
48
Prednisolone Approved, Vet_approved Phase 3,Phase 2 50-24-8 5755
49
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754
50
Captopril Approved Phase 3 62571-86-2 44093

Interventional clinical trials:

(show top 50) (show all 157)
# Name Status NCT ID Phase Drugs
1 Treatment Protocol for Relapsed Acute Promyelocytic Leukemia (APL) With Arsenic Unknown status NCT00196768 Phase 4 Arsenic trioxide;Trisenox
2 Combined Retinoic Acid,Arsenic Trioxide and Chemo for Newly-diagnosed APL Unknown status NCT01987297 Phase 4 ATRA+arsenic;ATRA+chemo
3 AIDA2000 - Risk-Adapted Therapy for Patients With Acute Promyelocytic Leukemia Unknown status NCT00180128 Phase 4 all-trans retinoid acid;idarubicin;mitoxantrone;daunorubicin;cytarabine
4 Treatment of Acute Promyelocytic Leukemia With All-Trans Retinoic Acid (ATRA) and Idarubicin (AIDA) Completed NCT00465933 Phase 4 AIDA
5 Treatment of Newly Diagnosed Patients With Acute Promyelocytic Leukemia (PETHEMA LPA 2005) Completed NCT00408278 Phase 4 ATRA;Idarubicina;Mitoxantrone;ARA-C
6 Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO) Completed NCT00504764 Phase 4 Arsenic Trioxide;ATRA
7 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
8 A Study for Improving the Outcome of Childhood Acute Promyeloid Leukemia Recruiting NCT02200978 Phase 4 ATO;RIF;ATRA;mitoxantrone;Ara-C;MTX;6MP
9 Single Agent Arsenic Trioxide in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia Unknown status NCT00517712 Phase 2, Phase 3 Single agent arsenic trioxide
10 Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Acute Promyelocytic Leukemia Unknown status NCT00002701 Phase 3 busulfan;cyclophosphamide;cytarabine;etoposide;idarubicin;mercaptopurine;methotrexate;mitoxantrone hydrochloride;thioguanine;tretinoin
11 Acute Promyelocytic Leukemia 2006 (APL) Unknown status NCT00378365 Phase 3
12 Therapeutic Effect and Safety Study of Decitabine in Elderly Acute Myeloid Leukemia Patients Unknown status NCT01633099 Phase 3 Decitabine
13 Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia in Remission Unknown status NCT00454168 Phase 3
14 Combination Chemotherapy, Biological Therapy, and Bone Marrow Transplantation in Treating Patients With Acute Myeloid Leukemia Unknown status NCT00002658 Phase 3 amsacrine;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin
15 Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia Completed NCT00866918 Phase 3 arsenic trioxide;mitoxantrone hydrochloride;idarubicin;tretinoin;cytarabine;mercaptopurine tablet;methotrexate
16 S0521, Combination Chemotherapy With or Without Gemtuzumab Followed By Tretinoin, Mercaptopurine, and Methotrexate or Observation in Treating Patients With Acute Promyelocytic Leukemia Completed NCT00492856 Phase 3 mercaptopurine;methotrexate;tretinoin
17 Tretinoin, Cytarabine, and Daunorubicin Hydrochloride With or Without Arsenic Trioxide Followed by Tretinoin With or Without Mercaptopurine and Methotrexate in Treating Patients With Acute Promyelocytic Leukemia Completed NCT00003934 Phase 3 tretinoin;daunorubicin hydrochloride;cytarabine;mercaptopurine;methotrexate;arsenic trioxide
18 Comparison of Two Treatments in Intermediate and High-risk Acute Promyelocytic Leukemia (APL) Patients to Assess Efficacy in 1st Hematological Complete Remission and Molecular Remission Completed NCT00962767 Phase 3 gemtuzumab ozogamicin;ATRA plus 6-MP and MTX
19 A Randomized Trial Assessing the Roles of AraC in Newly Diagnosed APL Promyelocytic Leukemia (APL) Completed NCT00591526 Phase 3 Arac
20 Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myeloid Leukemia Completed NCT00003436 Phase 3 amsacrine;asparaginase;cytarabine;daunorubicin hydrochloride;etoposide;methotrexate;mitoxantrone hydrochloride;therapeutic hydrocortisone
21 flt3L in Treating Patients With Acute Myeloid Leukemia Completed NCT00006223 Phase 3
22 Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation Completed NCT00004230 Phase 3 captopril;cyclophosphamide
23 Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation Completed NCT00014391 Phase 3 ribavirin
24 Itraconazole Compared With Fluconazole to Prevent Infections in Patients Undergoing Peripheral Stem Cell or Bone Marrow Transplantation Completed NCT00003883 Phase 3 fluconazole;itraconazole
25 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
26 Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia Recruiting NCT02688140 Phase 3 Arsenic trioxide;Idarubicin;Cytarabine;Tretinoin;Mitoxantrone;Mercaptopurine;Methotrexate
27 Treatment of Non-high-risk Acute Promyelocytic Leukemia (APL) With Realgar-Indigo Naturalis Formula (RIF) Recruiting NCT02899169 Phase 3 Realgar-Indigo naturalis formula;all-trans retinoic acid;Arsenic trioxide;Hydroxyurea
28 Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia Recruiting NCT02339740 Phase 3 Arsenic Trioxide;Cytarabine;Dexamethasone;Idarubicin;Mitoxantrone Hydrochloride;Tretinoin
29 Treatment Study for Children and Adolescents With Acute Promyelocitic Leukemia Recruiting NCT01226303 Phase 3 ATRA;ATRA + IDA
30 A PALG Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in AML Patients ≤ 60 Years Old Recruiting NCT03257241 Phase 3 A arm (DA-90);B arm (DAC);A arm (CLAG-M);B arm (FLAG-IDA)
31 An Efficacy and Safety Study Of Pracinostat In Combination With Azacitidine In Adults With Acute Myeloid Leukemia Recruiting NCT03151408 Phase 3 Pracinostat;Placebos;Azacitidine
32 Trial to Test the Effects of Adding 1 of 2 New Treatment Agents to Commonly Used Chemotherapy Combinations Recruiting NCT02272478 Phase 3 Arm A Mylotarg;Arm D Cladribine;AC220;Ganetespib
33 Phase III Trial in Acute Promyelocytic Leukemia Patients Active, not recruiting NCT00482833 Phase 3 arsenic trioxide;idarubicin;mercaptopurine;methotrexate;all-trans retinoic acid;all-trans retinoic acid (ATRA)
34 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
35 Proteasome Inhibition in Acute Promyelocytic Leukemia Unknown status NCT01950611 Phase 2 Bortezomib
36 Study of NRX 195183 Therapy for Patients With Relapsed or Refractory Acute Promyelocytic Leukemia Unknown status NCT00675870 Phase 2 NRX 195183 Soft Gelatin Capsule
37 FLAG+Ida With G-CSF Priming for Patients Younger Than 60 Years With Resistant AML Unknown status NCT00559221 Phase 2 FLAG+IDA
38 Fludarabine and Cytarabine as Continuous Infusion Plus G-CSF Priming for Elderly Patients With Resistant AML Unknown status NCT00529880 Phase 2 Fludarabine , cytarabine
39 Phase I/II Trial of ATRA and TCP in Patients With Relapsed or Refractory AML and no Intensive Treatment is Possible Unknown status NCT02261779 Phase 1, Phase 2 Tranylcypromine;Tretinoin
40 Light-Emitting Diode Therapy in Preventing Mucositis in Children Receiving Chemotherapy With or Without Radiation Therapy Before Bone Marrow Transplantation Unknown status NCT00036712 Phase 2
41 Arsenic Trioxide in Treating Patients With Refractory or Recurrent Acute Promyelocytic Leukemia Completed NCT00008697 Phase 1, Phase 2 arsenic trioxide
42 Monoclonal Antibody Therapy and Chemotherapy in Treating Patients With Acute Promyelocytic Leukemia in Remission Completed NCT00002609 Phase 2 cytarabine;idarubicin
43 Combination Chemotherapy in Treating Patients With Acute Promyelocytic Leukemia Completed NCT00276601 Phase 2 arsenic trioxide;cytarabine;daunorubicin hydrochloride;mercaptopurine;methotrexate;tretinoin
44 S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia Completed NCT00551460 Phase 2 arsenic trioxide;gemtuzumab ozogamicin;mercaptopurine;methotrexate;tretinoin
45 Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia Completed NCT00016159 Phase 2 arsenic trioxide;idarubicin;tretinoin
46 Safety, Efficacy, & Pharmacokinetic Study of Tamibarotene to Treat Patients With Relapsed or Refractory APL Completed NCT00520208 Phase 2 Tamibarotene
47 All-trans Retinoic Acid, and Arsenic +/- Gemtuzumab Completed NCT00413166 Phase 2 All-Trans Retinoic Acid (ATRA);Arsenic Trioxide (ATO);Idarubicin
48 Low Dose Arsenic Trioxide as a Potential Chemotherapy Protector Completed NCT01428128 Phase 2 Arsenic Trioxide
49 Pilot Clinical Trial of Pazopanib in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or at Initial Diagnosis When no Intensive Treatment is Possible Completed NCT01361334 Phase 2 Pazopanib
50 Study of Arsenic Trioxide in Small Cell Lung Cancer Completed NCT01470248 Phase 2 Arsenic Trioxide

Search NIH Clinical Center for Acute Promyelocytic Leukemia

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: leukemia, promyelocytic, acute

Genetic Tests for Acute Promyelocytic Leukemia

Genetic tests related to Acute Promyelocytic Leukemia:

# Genetic test Affiliating Genes
1 Acute Promyelocytic Leukemia 29 NUMA1 RARA

Anatomical Context for Acute Promyelocytic Leukemia

MalaCards organs/tissues related to Acute Promyelocytic Leukemia:

41
Myeloid, Bone, Bone Marrow, Skin, Brain, Lung, Testes

Publications for Acute Promyelocytic Leukemia

Articles related to Acute Promyelocytic Leukemia:

(show top 50) (show all 1304)
# Title Authors Year
1
Long-term control of refractory follicular lymphoma after treatment of secondary acute promyelocytic leukemia with arsenic trioxide (As<sub>2</sub>O<sub>3</sub>) and all-trans retinoic acid (ATRA). ( 29963527 )
2018
2
Reducing mortality in newly diagnosed standard-risk acute promyelocytic leukemia in elderly treated with arsenic trioxide requires major reduction of chemotherapy: a report by the French Belgian Swiss APL group. ( 29794147 )
2018
3
Chloroquine exerts antitumor effects on NB4 acute promyelocytic leukemia cells and functions synergistically with arsenic trioxide. ( 29434902 )
2018
4
Relapse of acute promyelocytic leukemia in the external auditory canal confirmed by PML/RARA dual-fusion and RARA break-apart fluorescence in situ hybridization. ( 29387977 )
2018
5
A Rare Case of Relapsed Pediatric Acute Promyelocytic Leukemia with Skin Involvement by Myeloid Sarcoma. ( 29650946 )
2018
6
Difference in causes and prognostic factors of early death between cohorts with de novo and relapsed acute promyelocytic leukemia. ( 29289982 )
2018
7
A unique clinical presentation of de novo acute promyelocytic leukemia as a myeloid sarcoma of the breast. ( 29931624 )
2018
8
Cell dynamics during differentiation therapy with all-trans retinoic acid in acute promyelocytic leukemia. ( 29845460 )
2018
9
Comparison of induction therapy in non-high risk acute promyelocytic leukemia with arsenic trioxide or in combination with ATRA. ( 29407588 )
2018
10
Dual origin of relapses in retinoic-acid resistant acute promyelocytic leukemia. ( 29795382 )
2018
11
Arsenic Trioxide Enhances the NK Cell Cytotoxicity Against Acute Promyelocytic Leukemia While Simultaneously Inhibiting Its Bio-Genesis. ( 29963052 )
2018
12
Inducing Apoptosis and Decreasing Cell Proliferation in Human Acute Promyelocytic Leukemia Through Regulation Expression of<i>CASP3</i>by Let-7a-5p Blockage. ( 29398802 )
2018
13
Acute promyelocytic leukemia presenting with features of metastatic osseous disease. ( 29892546 )
2018
14
Incident adverse events following therapy for acute promyelocytic leukemia. ( 29892554 )
2018
15
Philadelphia chromosome-negative acute promyelocytic leukemia manifesting after long-term imatinib treatment for chronic myeloid leukemia: a case report and literature review. ( 29404721 )
2018
16
Vernodalol mediates antitumor effects in acute promyelocytic leukemia cells. ( 29434929 )
2018
17
Deubiquitinase USP48 promotes ATRA-induced granulocytic differentiation of acute promyelocytic leukemia cells. ( 29901102 )
2018
18
Self-Assembled Nanocomplex for Co-Delivery of Arsenic-Retinoic Acid Prodrug into Acute Promyelocytic Leukemia Cells. ( 29843870 )
2018
19
Frontline therapy of acute promyelocytic leukemia: Randomized comparison of ATRA and intensified chemotherapy versus ATRA and anthracyclines. ( 29114972 )
2018
20
Prolonged treatment with arsenic trioxide (ATO) and all-trans-retinoic acid (ATRA) for relapsed acute promyelocytic leukemia previously treated with ATRA and chemotherapy. ( 29951912 )
2018
21
Arsenic trioxide promoting ETosis in acute promyelocytic leukemia through mTOR-regulated autophagy. ( 29362482 )
2018
22
Molecular Heterogeneity in Acute Promyelocytic Leukemia - a Single Center Experience from India. ( 29326799 )
2018
23
The impact of oral arsenic and all-trans-retinoic acid on coagulopathy in acute promyelocytic leukemia. ( 29232592 )
2018
24
Profiling and functional analysis of circular RNAs in acute promyelocytic leukemia and their dynamic regulation during all-trans retinoic acid treatment. ( 29844435 )
2018
25
Genomea89wide profiling of lncRNA expression patterns in patients with acute promyelocytic leukemia with differentiation therapy. ( 29956795 )
2018
26
Clinical pharmacokinetics and safety profile of single agent arsenic trioxide by continuous slow-rate infusion in patients with newly diagnosed acute promyelocytic leukemia. ( 29845392 )
2018
27
Improved long-term survival in all Sanz risk patients of newly diagnosed acute promyelocytic leukemia treated with a combination of retinoic acid and arsenic trioxide-based front-line therapy. ( 29862538 )
2018
28
Multi-omics profiling reveals a distinctive epigenome signature for high-risk acute promyelocytic leukemia. ( 29876014 )
2018
29
Secondary clonal hematologic neoplasia following successful therapy for acute promyelocytic leukemia (APL): A report of two cases and review of the literature. ( 29892552 )
2018
30
Apoptosis induction in acute promyelocytic leukemia cells through upregulation of <i>CEBPI+</i> by miR-182 blockage. ( 29911120 )
2018
31
Inhibition of CRL-NEDD8 pathway as a new approach to enhance ATRA-induced differentiation of acute promyelocytic leukemia cells. ( 29910671 )
2018
32
Recurrent RARB Translocations in Acute Promyelocytic Leukemia lacking RARA Translocation. ( 29921692 )
2018
33
Inducing cell proliferative prevention in human acute promyelocytic leukemia by miR-182 inhibition through modulation of CASP9 expression. ( 28298075 )
2017
34
Expression of the promyelocytic leukemia protein without the nuclear localization signal as a novel diagnostic marker for acute promyelocytic leukemia. ( 28075463 )
2017
35
miR-218 inhibits acute promyelocytic leukemia cell growth by targeting BMI-1. ( 29344251 )
2017
36
The clinical significance of FLT3 ITD mutation on the prognosis of adult acute promyelocytic leukemia. ( 29251252 )
2017
37
Epigallocatechin-3-gallate promotes all-trans retinoic acid-induced maturation of acute promyelocytic leukemia cells via PTEN. ( 28766684 )
2017
38
Influence of body mass index on incidence and prognosis of acute myeloid leukemia and acute promyelocytic leukemia: A meta-analysis. ( 29269861 )
2017
39
Clinical impact of<i>BAALC</i>expression in high-risk acute promyelocytic leukemia. ( 29296827 )
2017
40
Effect of ATRA and ATO on the expression of tissue factor in NB4 acute promyelocytic leukemia cells and regulatory function of the inflammatory cytokines TNF and IL-1I^. ( 28343272 )
2017
41
Pancreatitis in Acute Promyelocytic Leukemia: Drug-induced or Differentiation Syndrome? ( 29200694 )
2017
42
Acute Promyelocytic Leukemia: A Paradigm for Oncoprotein-Targeted Cure. ( 29136503 )
2017
43
Regulatory mechanism and functional analysis of S100A9 in acute promyelocytic leukemia cells. ( 28063140 )
2017
44
[Acute Promyelocytic Leukemia Developed during Imatinib Therapy for Gastrointestinal Stromal Tumors]. ( 28446275 )
2017
45
Rapamycin induces human acute promyelocytic leukemia cell HL-60 autophagic apoptosis. ( 29243797 )
2017
46
Gene and protein analysis reveals that p53 pathway is functionally inactivated in cytogenetically normal Acute Myeloid Leukemia and Acute Promyelocytic Leukemia. ( 28340577 )
2017
47
All-trans retinoic acid and arsenic trioxide fail to derepress the monocytic differentiation driver Irf8 in acute promyelocytic leukemia cells. ( 28492552 )
2017
48
Identification of novel recurrent<i>STAT3-RARA</i>fusions in acute promyelocytic leukemia lacking t(15;17)(q22;q12)/<i>PML-RARA</i>. ( 29237593 )
2017
49
Clinical impact of galectin-3 in newly diagnosed t (15;17)(q22;q21)/PML-RARa acute promyelocytic leukemia treated with all-trans retinoic acid and arsenic trioxide-based regimens. ( 28238096 )
2017
50
Progress and criticalities in the management of acute promyelocytic leukemia. ( 29245895 )
2017

Variations for Acute Promyelocytic Leukemia

Copy number variations for Acute Promyelocytic Leukemia from CNVD:

7 (show all 28)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 17351 1 142487224 245120412 Gain Acute promyelocytic leukemia
2 29128 1 227843862 227867765 Deletion EGLN1 Acute promyelocytic leukemia
3 44777 10 62496958 68046104 Deletion Acute promyelocytic leukemia
4 71119 12 6755671 29248257 Deletion Acute promyelocytic leukemia
5 78273 13 49630676 50510777 Deletion DLEU7 Acute promyelocytic leukemia
6 78274 13 49630676 50510777 Deletion FAM10A4 Acute promyelocytic leukemia
7 78275 13 49630676 50510777 Deletion GUCY1B2 Acute promyelocytic leukemia
8 78767 13 56784440 114051465 Duplication Acute promyelocytic leukemia
9 93669 15 57244668 100182183 Duplication Acute promyelocytic leukemia
10 94970 15 72224840 100192115 Duplication Acute promyelocytic leukemia
11 108134 17 18901 21459693 Deletion Acute promyelocytic leukemia
12 108602 17 21491135 35542587 Duplication Acute promyelocytic leukemia
13 123386 18 7192739 7657575 Duplication PTPRM Acute promyelocytic leukemia
14 157044 21 1 48129895 Tri Acute promyelocytic leukemia
15 158722 21 36234195 46924583 Duplication Acute promyelocytic leukemia
16 181722 4 125190507 126521903 Deletion Acute promyelocytic leukemia
17 214094 6 5545437 8054930 Deletion Acute promyelocytic leukemia
18 220370 7 137795618 137920872 Translate TIF1 Acute promyelocytic leukemia
19 226739 7 61522282 158554645 Deletion Acute promyelocytic leukemia
20 228938 7 85414972 86445002 Deletion DMTF1 Acute promyelocytic leukemia
21 228939 7 85414972 86445002 Deletion GRM3 Acute promyelocytic leukemia
22 228940 7 85414972 86445002 Deletion KIAA1324L Acute promyelocytic leukemia
23 230737 8 1 146364022 Tri Acute promyelocytic leukemia
24 233093 8 122607785 132092760 Duplication Acute promyelocytic leukemia
25 254363 9 64207745 111479523 Deletion Acute promyelocytic leukemia
26 256567 9 94435025 94710006 Duplication C9orf3 Acute promyelocytic leukemia
27 256568 9 94435025 94710006 Duplication FBP1 Acute promyelocytic leukemia
28 256569 9 94435025 94710006 Duplication FBP2 Acute promyelocytic leukemia

Expression for Acute Promyelocytic Leukemia

Search GEO for disease gene expression data for Acute Promyelocytic Leukemia.

Pathways for Acute Promyelocytic Leukemia

Pathways related to Acute Promyelocytic Leukemia according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.75 MIR126 MIR15A MIR16-1 MIR210 MIR223 MIR23A
2 10.96 MIR16-1 MIR210 MIR23A MIRLET7D
3 10.88 MIRLET7A3 MIRLET7C MIRLET7D
4 10.71 PML RARA ZBTB16

GO Terms for Acute Promyelocytic Leukemia

Cellular components related to Acute Promyelocytic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.28 MIR126 MIR15A MIR16-1 MIR210 MIR223 MIR23A
2 spindle pole centrosome GO:0031616 8.96 NPM1 NUMA1

Biological processes related to Acute Promyelocytic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 9.91 MIRLET7C NPM1 PML RARA STAT5B TBL1XR1
2 negative regulation of cell proliferation GO:0008285 9.63 MIR15A MIR16-1 NPM1 PML RARA ZBTB16
3 negative regulation of angiogenesis GO:0016525 9.54 MIR15A MIR16-1 PML
4 negative regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis GO:1903588 9.48 MIR15A MIR16-1
5 myeloid cell differentiation GO:0030099 9.46 PML ZBTB16
6 negative regulation of vascular associated smooth muscle cell migration GO:1904753 9.4 MIR15A MIR223
7 retinoic acid receptor signaling pathway GO:0048384 9.32 PML RARA
8 negative regulation of cell chemotaxis to fibroblast growth factor GO:1904848 9.26 MIR15A MIR16-1
9 miRNA mediated inhibition of translation GO:0035278 9.26 MIR15A MIR16-1 MIR210 MIRLET7A3
10 gene silencing by miRNA GO:0035195 9.17 MIR126 MIR15A MIR16-1 MIR210 MIR223 MIR23A

Molecular functions related to Acute Promyelocytic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein domain specific binding GO:0019904 9.26 NUMA1 PRKAR1A RARA ZBTB16
2 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.17 MIR126 MIR15A MIR16-1 MIR210 MIR223 MIR23A

Sources for Acute Promyelocytic Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....